• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Telecon Memo, November 21, 2011 - Flucelvax

 

Date: November 21, 2011
 
From: Carla Vincent, CBER RIMS User Fees
 
Through: David Dickerson, CSO DVRPA
 
John Barry, Head of Regulatory Affairs North America, Novartis
 
Summary: I contacted Mr. Barry to indicate that a user fee had not been received from Novartis for BLA STN# 125408, Influenza Vaccine (MDCK Cells). Mr. Barry said this was an inadvertent mistake and would see that payment was wired immediately. I provided the following wire payment information.
 
Wire Transfer Payment
 
US Department of Treasury
TREAS NYC
33 Liberty Street
New York, NY 10045
FDA Deposit Account Number:  75060099
US Department of Treasury routing/transit number:  021030004
SWIFT Number: FRNYUS33
 
Mr. Barry thanked me for calling and the call ended pleasantly. (Note: Because the payment was received on 11/22/2011, an Unacceptable for Filing letter was not issued to Novartis. DVRPA decided to convey the new action due date via the acknowledgment letter.)